Veralipride-induced acute coronary syndrome unmasking a non-secreting pheochromocytoma.
The administration of veralipride, a centrally acting dopaminergic type 2 (DA2) receptor antagonist, can decrease hot flushes and improve bone density in post-menopausal women (1). Therefore, it entails an alternative to hormone replacement therapy (HRT) in women who have contraindications to estrogen (1). We herein describe the case of a 52-yr-old lady who presented with an acute coronary syndrome shortly after taking veralipride. Based on knowledge that DA2 receptor antagonists trigger catecholamine release (2), a pheochromocytoma was suspected and thereafter diagnosed and excised. Therefore, this is the first case reporting on veralipride unmasking a silent pheochromocytoma.
Montemurro
D
D
DMCS-Internal Medicine 4, University of Padua, Padua, Italy.
Rossi
G P
GP
D000208:Acute Disease; D000310:Adrenal Gland Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D003327:Coronary Disease / Q000139:chemically induced*; D018492:Dopamine Antagonists / Q000009:adverse effects; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D010673:Pheochromocytoma / Q000175:diagnosis* / Q000378:metabolism; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D018492:Dopamine Antagonists; D013469:Sulpiride; C027429:veralipride